Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing New data using Signatera to monitor treatment response with an immunotherapy-based regimen in hepatocellular carcinoma [19-May-2020] SAN CARLOS, Calif. , May 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global le
May 19, 2020
· 6 min read